Zobrazeno 1 - 10
of 196
pro vyhledávání: '"Chandrasekaran Padmapriyadarsini"'
Autor:
Prathiksha Giridharan, Rakesh P. Suseela, Tandin Zangpo, Rita Bhandari Joshi, Mizaya Cader, Fathiyah Isbaniah, Banurekah Velayudham, Fathimath Nazla Rafeeg, Antonio da Cruz Santos, Naveen Prakash Shah, Manu Mathew, Leyanna Susan George, Nivedita Gupta, Chandrasekaran Padmapriyadarsini
Publikováno v:
Public Health in Practice, Vol 8, Iss , Pp 100518- (2024)
Objectives: Countries in the South East Asian region face similar challenges in control of infectious diseases. There is limited access to experiences and learnings of neighboring countries. The Indian Council - of Medical Research (ICMR) has establi
Externí odkaz:
https://doaj.org/article/1f00077c589542df90e67fd0d61403ca
Autor:
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTAZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford U
Externí odkaz:
https://doaj.org/article/8b89a3e8f8ac470894c80a7c06493aa6
Autor:
Rupak Singla, Amitesh Gupta, Vikas Kumar, Chandrasekaran Padmapriyadarsini, Devika Tayal, Shweta Anand, Abhishek Faye, AK Hemanth Kumar, Madhumita Paul Choudhary
Publikováno v:
Monaldi Archives for Chest Disease (2024)
This study was carried out to assess the role of therapeutic drug monitoring of crucial first-line anti-tubercular drugs: rifampicin (R) and isoniazid (H) among 75 non-responding proven drug-sensitive tuberculosis patients on treatment followed by in
Externí odkaz:
https://doaj.org/article/035728e68eb645ce81129d8100613a98
Autor:
Pavan Kumar Nathella, Chandrasekaran Padmapriyadarsini, Arul Nancy, Kushiyasri Karunanithi, Nandhini Selvaraj, Rachel Mariam Renji, B.M. Shrinivasa, Subash Babu
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e32643- (2024)
We investigated how BCG vaccination affects the levels of certain eicosanoids, namely Leukotriene B4, 15-epimer of LXA4, prostaglandin F2, Lipoxin A4, Prostaglandin E2 and Resolvin D1 in the plasma of healthy elderly individuals (aged 60–80) before
Externí odkaz:
https://doaj.org/article/98b62fd3c7874329b4fac30aafaa2f5a
Autor:
Amarendra Mahapatra, Kannan Thiruvengadam, Dina Nair, Chandrasekaran Padmapriyadarsini, Beena Thomas, Sanghamitra Pati, Gandham Bulliyya, Dasarathi Das, Jayeeta Chowdhury, Anand Bang, Soumya Swaminathan
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0305855 (2024)
BackgroundBy encouraging treatment adherence and lowering mortality, dietary supplements can serve as adjuvant therapy for the success of medical interventions. We determined the effect of locally accessible food supplements on treatment outcomes, an
Externí odkaz:
https://doaj.org/article/8c090550e5fe4ccfb86827ac97c1dd62
Autor:
Banurekha Velayutham, Lavanya Jayabal, Basilea Watson, Saraswathy Jagadeesan, Chandra Suresh, Dina Nair, Radha Gopalaswamy, Bella Devaleenal, Sriram Selvaraju, Chandrasekaran Padmapriyadarsini
Publikováno v:
Indian Journal of Community Medicine, Vol 48, Iss 1, Pp 103-107 (2023)
Introduction: Early initiation of drug susceptibility testing (DST) guided anti-tuberculosis treatment benefits the patient in terms of better treatment outcomes and possibly reduces the transmission of tuberculosis (TB) disease in the community. To
Externí odkaz:
https://doaj.org/article/97dea7457b9543aa9afb965a86852fd7
Autor:
Leeberk Raja Inbaraj, Hemant Deepak Shewade, Jefferson Daniel, Vignes Anand Srinivasalu, Jabez Paul, S. Satish, Richard Kirubakaran, Chandrasekaran Padmapriyadarsini
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundWe aimed to determine the effectiveness and safety of the Levofloxacin-containing regimen that the World Health Organization is currently recommending for the treatment of Isoniazid mono-resistant pulmonary Tuberculosis.MethodsOur eligible
Externí odkaz:
https://doaj.org/article/c9116d33006543ba998d92afbdf7e14f
Autor:
Priya Rajendran, Chandrasekaran Padmapriyadarsini, Naveenkumar Nagarajan, Roja Samyuktha, Vadivu Govindaraju, Radhika Golla, Shanmugavel Ashokkumar, Sivakumar Shanmugam
Publikováno v:
Pathogens, Vol 12, Iss 10, p 1249 (2023)
M. kansasii is the most common non-tuberculous mycobacteria, known to be causing pulmonary and extrapulmonary diseases in humans. Based on molecular methods, M. kansasii has been previously classified into seven different subtypes. Now, based on whol
Externí odkaz:
https://doaj.org/article/5ebe813768bc4d42a4fe030e420a81cb
Autor:
Malaisamy Muniyandi, Paranchi Murugesan Ramesh, William A. Wells, Umesh Alavadi, Suvanand Sahu, Chandrasekaran Padmapriyadarsini
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 8, Iss 8, p 411 (2023)
Objective: To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods: In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6–9 month
Externí odkaz:
https://doaj.org/article/8364645f731f4b13bdc32877c4faf795
Autor:
Nathella Pavan Kumar, Chandrasekaran Padmapriyadarsini, Anuradha Rajamanickam, Perumal Kannabiran Bhavani, Arul Nancy, Bharathi Jeyadeepa, Nandhini Selvaraj, Dinesh Ashokan, Rachel Mariam Renji, Vijayalakshmi Venkataramani, Srikanth Tripathy, Subash Babu
Publikováno v:
International Journal of Infectious Diseases, Vol 110, Iss , Pp 98-104 (2021)
Objective: BCG can improve the response to vaccines directed against viral infections, and also, BCG vaccination reduces all-cause mortality, most likely by protecting against unrelated infections. However, the effect of BCG vaccination on dendritic
Externí odkaz:
https://doaj.org/article/cd353000be31426da076ee8aacbd3544